Ascelia Pharma Signs Clinical Collaboration
Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

by | Sep 22, 2021

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluridine and tipiracil) film-coated tablets for oral use. The combination of Oncoral and LONSURF is investigational at this time and not approved for use in gastric cancer or any other disease.

Press inquiries should be adressed to:

Peter Benson, Msc

Chairman & General Partner